COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF NIVOLUMAB VS. DOCETAXEL AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Shah, S.
    Matthews, S. E.
    Sarasani, S.
    Noel, S.
    Blanchette, C. M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [42] The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in Germany.
    Bischoff, H.
    Hermes, A.
    Gatzemeier, U.
    Heigener, D. F.
    Cesaro-Tadic, S.
    Walzer, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Atezolizumab in non-squamous non-small cell lung cancer
    Akamine, Takaki
    Toyokawa, Gouji
    Tagawa, Tetsuzo
    Seto, Takashi
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S3155 - S3159
  • [44] Cost-Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
    Kuhlmann, A.
    Schmidt, T.
    Treskova, M.
    Golpon, H.
    Welte, T.
    Von der Schulenburg, J. -Graf
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2303
  • [45] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [46] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Hu, Shanlian
    Tang, Zhiliu
    Harrison, James P.
    Hertel, Nadine
    Penrod, John R.
    May, Jessica R.
    Juarez-Garcia, Ariadna
    Holdgate, Orban
    [J]. PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 273 - 284
  • [47] Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
    Shanlian Hu
    Zhiliu Tang
    James P. Harrison
    Nadine Hertel
    John R. Penrod
    Jessica R. May
    Ariadna Juarez-Garcia
    Orban Holdgate
    [J]. PharmacoEconomics - Open, 2023, 7 : 273 - 284
  • [48] Management and treatment costs of non-squamous metastatic or locally advanced non-small cell lung cancer
    Pruszko, Cezary
    Jachimowicz, Michal
    Kalinowska, Agnieszka
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 (02): : 63 - 67
  • [49] WORDS (EXCLUDING TATLE AND AUTHORS: 300) TITLE: COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF SECOND-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
    Gonzalez Garcia, P.
    Felip, E.
    Garrido, P.
    Trigo, J.
    Ortega-Joaquin, N.
    Echave, M.
    Jimenez, S.
    Oyaguez, I
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A733
  • [50] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
12345